Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport (NASDAQ: CYRX) reported its Q3 2024 financial results. Life Sciences Services revenue increased by 9% YoY, with BioStorage/BioServices revenue up 12%. The company supported 691 global clinical trials as of September 30, 2024. Q3 2024 total revenue was $56.7 million, up 1% YoY. Life Sciences Products revenue fell by 14% YoY. The company reaffirmed its full-year 2024 revenue guidance of $225-$235 million. Gross margin improved to 44.8% from 43.2% YoY. Net income was $0.8 million for Q3 2024, compared to a net loss of $13.3 million in Q3 2023. Adjusted EBITDA was a negative $2.4 million, better than the negative $3.1 million in Q3 2023. Cryoport repurchased $175 million in Convertible Senior Notes due in 2026 for $154.5 million. The company launched IntegriCell™ Cryopreservation Solution in October 2024.
Cryoport (Nasdaq: CYRX) announced it will release its third quarter 2024 financial results on November 7, 2024 after U.S. markets close. The company will issue a document titled 'Cryoport Third Quarter 2024 in Review' at 4:05 p.m. ET, providing financial and operational performance details. Management will host a Q&A conference call at 5:00 p.m. ET the same day, accompanied by a slide deck. The call will be available for replay until November 14, 2024, accessible via the company's website or dial-in numbers.
Cryoport (NASDAQ: CYRX) and Gulf Coast Regional Blood Center (GCRBC) have announced a strategic alliance to enhance cellular therapy services. This partnership coincides with the grand opening of Cryoport's IntegriCell™ Houston facility. The collaboration combines GCRBC's Cellular Life Solutions program, specializing in allogeneic donor recruitment and apheresis collection, with Cryoport's cryopreservation and biologistics expertise.
The alliance aims to enhance the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment. GCRBC's program is located less than two miles from Cryoport's Houston campus, enabling efficient local transport through Cryoport's Cryoshuttle® service. This partnership is expected to create a comprehensive and unified service offering for the life sciences community, streamlining processes and accelerating the development of cell therapies.
Cryoport, Inc. (NASDAQ: CYRX) and TMRW Life Sciences have announced a strategic partnership to provide fertility clinics with complete solutions for secure specimen management and transport. This collaboration aims to address the growing demand for offsite storage of frozen specimens in fertility clinics.
The partnership combines TMRW's FDA-cleared automated specimen management and storage platform with Cryoport Systems' expertise in biologistics and transport. Both companies are ISO-certified, ensuring high-quality standards. TMRW offers HIPAA-compliant, military-grade data security with SOC II and HITRUST certifications, while Cryoport brings over a decade of experience in reproductive medicine biologistics and its Cryoportal® Logistics Management Platform.
This collaboration is expected to provide fertility clinics with comprehensive, trusted solutions for managing their growing specimen inventories with enhanced safety and reliability.
Cryoport, Inc. (NASDAQ: CYRX) and VGXI, Inc. have announced a strategic partnership to support biopharmaceutical companies in developing cell and gene therapies and mRNA-based treatments. The collaboration will commence in October 2024, with Cryoport Systems providing biostorage and bioservices from its Houston, Texas facility for plasmid DNA products manufactured at VGXI's facilities in The Woodlands and Conroe, Texas.
This partnership combines VGXI's expertise in plasmid DNA manufacturing with Cryoport's integrated supply chain solutions, including shipping services, data solutions, and comprehensive support services. The collaboration aims to enhance support for biopharmaceutical companies developing next-generation therapies, ensuring seamless final delivery to VGXI's end customers.
Cryoport, Inc. (NASDAQ: CYRX) has launched its IntegriCell™ cryopreservation services solution with the opening of a new facility at its Houston campus. The state-of-the-art facility is dedicated to the standardized cryopreservation of leukapheresis material, integrating with Cryoport's end-to-end global temperature-controlled supply chain platform to support cell-based therapies.
The IntegriCell platform aims to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality, and product stability. The Houston site also supports GMP-compliant biostorage and a full suite of bioservices, including secondary packaging, labeling, kit production, and logistics capabilities.
Cryoport's CEO, Jerrell Shelton, stated that the new facility expands their presence in Houston and is a significant milestone in providing integrated supply chain solutions for cell and gene therapies. The company believes IntegriCell will offer the industry's first complete solution for optimized cellular starting materials, potentially accelerating treatment delivery and opening new revenue streams.
Cryoport, Inc. (NASDAQ: CYRX) and SK pharmteco have announced a strategic collaboration to provide integrated logistics and manufacturing services for biotechnology and pharmaceutical companies. Cryoport will support SK pharmteco's contract manufacturing of small molecule and cell and gene therapy products with its end-to-end supply chain services, including shipping systems, data solutions, and bioservices.
Jerrell Shelton, CEO of Cryoport, expressed enthusiasm about the partnership, highlighting its alignment with Cryoport's goal to diversify revenue streams, particularly from commercial cell and gene therapies. Dana Cipriano, VP of Analytical Services at SK pharmteco, emphasized the importance of supply chain safety and integrity in the growing cell and gene therapy industry, reaffirming their commitment to providing high-quality services tailored to customer and patient needs.
Cryoport reported Q2 2024 financial results, showing sequential revenue improvement across all businesses. Key highlights include:
- Commercial Cell & Gene Therapy revenue increased 51% year-over-year and 20% sequentially
- A record 684 global clinical trials supported as of June 30, 2024
- Cost reduction initiatives expected to result in $22 million annual savings
- Updated 2024 full-year revenue guidance of $225-$235 million
- Q2 2024 total revenue was $57.6 million, up 1% year-over-year
- Gross margin improved to 43.7% in Q2 2024 from 43.4% in Q2 2023
- Net loss of $78.0 million in Q2 2024, primarily due to a $63.8 million impairment charge
- $427.1 million in cash and investments as of June 30, 2024
The company expects continued softness in Life Sciences Products demand but anticipates sequential growth in Life Sciences Services for the remainder of 2024.
Cryoport announced a $200 million repurchase program for common stock and convertible senior notes, effective until December 31, 2027. The company also agreed to repurchase $160 million of its 0.75% Convertible Senior Notes due in 2026 at an 11.5% discount, valued at $141.6 million plus accrued interest. This strategic move aims to reduce the outstanding debt to approximately $186.2 million, down from an initial $402.5 million. The transactions are expected to close on August 9, 2024, subject to customary closing conditions. CEO Jerrell Shelton emphasized the company's strong cash position, which enables debt reduction while maintaining liquidity for long-term growth.
Cryoport (Nasdaq: CYRX), a global leader in life sciences supply chain solutions, has announced it will report its second quarter 2024 financial results on August 6, 2024, after U.S. markets close. The company will release a document titled 'Cryoport Second Quarter 2024 in Review' at 4:05 p.m. ET, providing a comprehensive review of financial and operational performance, along with a general business update.
A conference call will be held the same day at 5:00 p.m. ET, featuring a Q&A session with management addressing questions from the investment community. The call will be accompanied by a slide deck and can be accessed via phone or webcast. A recording of the call will be available on the company's website for a time, with a dial-in replay accessible until August 13, 2024.